Mapping the intellectual structure and landscape of colorectal cancer immunotherapy: A bibliometric analysis

References

• Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–14. doi:10.3322/caac.21660.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2020. CA Cancer J Clin. 2020;70:145–64. doi:10.3322/caac.21601.
   PubMed Web of Science ®Google Scholar
• Edwards BK, Ward E, Kohler BA, Eheman C, Zauber AG, Anderson RN, Jemal A, Schymura MJ, Lansdorp-Vogelaar I, Seeff LC, et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010;116(3):544–73. doi:10.1002/cncr.24760.
   PubMed Web of Science ®Google Scholar
• Sargent D, Sobrero A, Grothey A, O’Connell MJ, Buyse M, Andre T, Zheng Y, Green E, Labianca R, O’Callaghan C, et al. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2009;27(6):872–7. doi:10.1200/JCO.2008.19.5362.
   PubMed Web of Science ®Google Scholar
• Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018;8(9):1069–86. doi:10.1158/2159-8290.CD-18-0367.
   PubMed Web of Science ®Google Scholar
• Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–20. doi:10.1056/NEJMoa1500596.
   PubMed Web of Science ®Google Scholar
• Overman MJ, Lonardi S, Wong KYM, Lenz H-J, Gelsomino F, Aglietta M, Morse MA, Van Cutsem E, McDermott R, Hill A, et al. Durable clinical benefit With Nivolumab plus Ipilimumab in DNA mismatch repair–deficient/microsatellite instability–high metastatic colorectal cancer. J Clin Oncol. 2018;36(8):773–9. doi:10.1200/JCO.2017.76.9901.
   PubMed Web of Science ®Google Scholar
• Sautès-Fridman C, Petitprez F, Calderaro J, Fridman WH. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat Rev Cancer. 2019;19(6):307–25. doi:10.1038/s41568-019-0144-6.
   PubMed Web of Science ®Google Scholar
• Helmink BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, Yizhak K, Sade-Feldman M, Blando J, Han G, et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020;577(7791):549–55. doi:10.1038/s41586-019-1922-8.
   PubMed Web of Science ®Google Scholar
• Zhang C, Wang X-Y, Zuo J-L, Wang X-F, Feng X-W, Zhang B, Li Y-T, Yi C-H, Zhang P, Ma X-C, et al. Localization and density of tertiary lymphoid structures associate with molecular subtype and clinical outcome in colorectal cancer liver metastases. J Immunother Cancer. 2023;11(2):e006425. doi:10.1136/jitc-2022-006425.
   PubMed Web of Science ®Google Scholar
• Ma D, Guan B, Song L, Liu Q, Fan Y, Zhao L, Wang T, Zhang Z, Gao Z, Li S, et al. A bibliometric analysis of exosomes in cardiovascular diseases from 2001 to 2021. Front Cardiovasc Med. 2021;8:734514. doi:10.3389/fcvm.2021.734514.
   PubMed Web of Science ®Google Scholar
• Chen CC. CiteSpace II: detecting and visualizing emerging trends and transient patterns in scientific literature. J Am Soc Inf Sci. 2006;57(3):359–77. doi:10.1002/asi.20317.
   Web of Science ®Google Scholar
• Trinchieri G. Cancer and inflammation: an old intuition with rapidly evolving new concepts. Annu Rev Immunol. 2012;30(1):677–706. doi:10.1146/annurev-immunol-020711-075008.
   PubMedGoogle Scholar
• Liang Y-D, Li Y, Zhao J, Wang X-Y, Zhu H-Z, Chen X-H. Study of acupuncture for low back pain in recent 20 years: a bibliometric analysis via CiteSpace. J Pain Res. 2017;10:951–64. doi:10.2147/JPR.S132808.
   PubMed Web of Science ®Google Scholar
• Hirsch JE. An index to quantify an individual’s scientific research output. Proc Natl Acad Sci USA. 2005;102(46):16569–72. doi:10.1073/pnas.0507655102.
   PubMed Web of Science ®Google Scholar
• Casak SJ, Marcus L, Fashoyin-Aje L, Mushti SL, Cheng J, Shen Y-L, Pierce WF, Her L, Goldberg KB, Theoret MR, et al. FDA approval summary: pembrolizumab for the first-line treatment of patients with MSI-H/dMMR advanced unresectable or metastatic colorectal carcinoma. Clin Cancer Res. 2021;27(17):4680–4. doi:10.1158/1078-0432.CCR-21-0557.
   PubMed Web of Science ®Google Scholar
• Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409–13. doi:10.1126/science.aan6733.
   PubMed Web of Science ®Google Scholar
• Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A, Sasayama S, Mizoguchi A, Hiai H, Minato N, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science. 2001;291(5502):319–22. doi:10.1126/science.291.5502.319.
   PubMed Web of Science ®Google Scholar
• Chen L. Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity. Nat Rev Immunol. 2004;4(5):336–47. doi:10.1038/nri1349.
   PubMed Web of Science ®Google Scholar
• Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of Lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. 1999;11(2):141–51. doi:10.1016/S1074-7613(00)80089-8.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–54. doi:10.1056/NEJMoa1200690.
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL, et al. Phase I study of single-agent anti–programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. JCO. 2010;28(19):3167–75. doi:10.1200/JCO.2009.26.7609.
   PubMed Web of Science ®Google Scholar
• Phillips SM, Banerjea A, Feakins R, Li SR, Bustin SA, Dorudi S. Tumour-infiltrating lymphocytes in colorectal cancer with microsatellite instability are activated and cytotoxic. Br J Surg. 2004;91(4):469–75. doi:10.1002/bjs.4472.
   PubMed Web of Science ®Google Scholar
• Llosa NJ, Cruise M, Tam A, Wicks EC, Hechenbleikner EM, Taube JM, Blosser RL, Fan H, Wang H, Luber BS, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 2015;5(1):43–51. doi:10.1158/2159-8290.CD-14-0863.
   PubMed Web of Science ®Google Scholar
• Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz H-J, Morse MA, Desai J, Hill A, Axelson M, Moss RA, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18(9):1182–91. doi:10.1016/S1470-2045(17)30422-9.
   PubMed Web of Science ®Google Scholar
• André T, Shiu K-K, Kim TW, Jensen BV, Jensen LH, Punt C, Smith D, Garcia-Carbonero R, Benavides M, Gibbs P, et al. Pembrolizumab in microsatellite-instability–high advanced colorectal cancer. N Engl J Med. 2020;383(23):2207–18. doi:10.1056/NEJMoa2017699.
   PubMed Web of Science ®Google Scholar
• Pei L, Liu Y, Liu L, Gao S, Gao X, Feng Y, Sun Z, Zhang Y, Wang C. Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1/PD-L1 immunotherapy for solid cancers. Mol Cancer. 2023;22(1):29. doi:10.1186/s12943-023-01731-z.
   PubMed Web of Science ®Google Scholar
• Chew V, Lai L, Pan L, Lim CJ, Li J, Ong R, Chua C, Leong JY, Lim KH, Toh HC, et al. Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses. Proc Natl Acad Sci USA. 2017;114(29):E5900–9. doi:10.1073/pnas.1706559114.
   PubMed Web of Science ®Google Scholar
• Novikova MV, Khromova NV, Kopnin PB. Components of the hepatocellular carcinoma microenvironment and their role in tumor progression. Biochemistry (Mosc). 2017;82(8):861–73. doi:10.1134/S0006297917080016.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020;17(8):807–21. doi:10.1038/s41423-020-0488-6.
   PubMed Web of Science ®Google Scholar
• Pandey PR, Young KH, Kumar D, Jain N. RNA-mediated immunotherapy regulating tumor immune microenvironment: next wave of cancer therapeutics. Mol Cancer. 2022;21(1):58. doi:10.1186/s12943-022-01528-6.
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34. doi:10.1056/NEJMoa1504030.
   PubMed Web of Science ®Google Scholar
• Tavazoie MF, Pollack I, Tanqueco R, Ostendorf BN, Reis BS, Gonsalves FC, Kurth I, Andreu-Agullo C, Derbyshire ML, Posada J, et al. LXR/ApoE activation restricts innate immune suppression in cancer. Cell. 2018;172(4):825–840.e18. doi:10.1016/j.cell.2017.12.026.
   PubMed Web of Science ®Google Scholar
• Weng J, Li S, Zhu Z, Liu Q, Zhang R, Yang Y, Li X. Exploring immunotherapy in colorectal cancer. J Hematol Oncol. 2022;15(1):95. doi:10.1186/s13045-022-01294-4.
   PubMed Web of Science ®Google Scholar
• Yu G, Wu Y, Wang W, Xu J, Lv X, Cao X, Wan T. Low-dose decitabine enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by re-modulating the tumor microenvironment. Cell Mol Immunol. 2018;16:401–9. doi:10.1038/s41423-018-0026-y.
   PubMed Web of Science ®Google Scholar
• Liu C, Wang X, Qin W, Tu J, Li C, Zhao W, Ma L, Liu B, Qiu H, Yuan X. Combining radiation and the ATR inhibitor berzosertib activates STING signaling and enhances immunotherapy via inhibiting SHP1 function in colorectal cancer. Cancer Commun. 2023;43(4):435–54. doi:10.1002/cac2.12412.
   Web of Science ®Google Scholar
• Doleschel D, Hoff S, Koletnik S, Rix A, Zopf D, Kiessling F, Lederle W. Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth. J Exp Clin Cancer Res. 2021;40(1):288. doi:10.1186/s13046-021-02043-0.
   PubMed Web of Science ®Google Scholar
• Wang S, Song Y, Cao K, Zhang L, Fang X, Chen F, Feng S, Yan F. Photothermal therapy mediated by gold nanocages composed of anti-PDL1 and galunisertib for improved synergistic immunotherapy in colorectal cancer. Acta Biomater. 2021;134:621–32. doi:10.1016/j.actbio.2021.07.051.
   PubMed Web of Science ®Google Scholar
• Jiang S-S, Xie Y-L, Xiao X-Y, Kang Z-R, Lin X-L, Zhang L, Li C-S, Qian Y, Xu P-P, Leng X-X, et al. Fusobacterium nucleatum-derived succinic acid induces tumor resistance to immunotherapy in colorectal cancer. Cell Host Microbe. 2023;31(5):781–797.e9. doi:10.1016/j.chom.2023.04.010.
   PubMed Web of Science ®Google Scholar
• Chen L, Zhao R, Shen J, Liu N, Zheng Z, Miao Y, Zhu J, Zhang L, Wang Y, Fang H, et al. Antibacterial Fusobacterium nucleatum‐mimicking nanomedicine to selectively eliminate tumor‐colonized bacteria and enhance immunotherapy against colorectal cancer. Adv Mater. 2023;35:e2306281. doi:10.1002/adma.202306281.
   PubMed Web of Science ®Google Scholar
• Gao G, Shen S, Zhang T, Zhang J, Huang S, Sun Z, Zhang H. Lacticaseibacillus rhamnosus probio-M9 enhanced the antitumor response to anti-PD-1 therapy by modulating intestinal metabolites. EBioMedicine. 2023;91:104533. doi:10.1016/j.ebiom.2023.104533.
   PubMed Web of Science ®Google Scholar
• Bell HN, Huber AK, Singhal R, Rebernick RJ, Kumar R, Das NK, Kerk SA, Sajjakulnukit P, Solanki S, James JG, et al. Microenvironmental ammonia enhances T cell exhaustion in colorectal cancer. Cell Metab. 2022;35:134–49.e6. doi:10.1016/j.cmet.2022.11.013.
   PubMed Web of Science ®Google Scholar
• Yue T, Li J, Zhu J, Zuo S, Wang X, Liu Y, Liu J, Liu X, Wang P, Chen S. Hydrogen sulfide creates a favorable immune microenvironment for colon cancer. Cancer Res. 2022;83:595–612. doi:10.1158/0008-5472.CAN-22-1837.
   Web of Science ®Google Scholar
• Ma L, Ma J, Teng M, Li Y. Visual analysis of colorectal cancer immunotherapy: a bibliometric analysis from 2012 to 2021. Front Immunol. 2022;13. doi:10.3389/fimmu.2022.843106.
   Web of Science ®Google Scholar